Evicenter
MarkdownMedical informationP&T meetings
Lanifibranor (IVA337)

Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis

Manufacturer
Inventiva
Last updated
220 sources

Executive summary

Lanifibranor efficacy and safety

6 evidence topics · 33 sources

Summary: regulatory status, NATiV3 design, and NATiV3 status

Lanifibranor is an investigational oral pan-PPAR agonist that “has not been approved for use by any regulatory authority”. The FDA granted Fast Track designation for NASH and Breakthrough Therapy designation for NASH in October 2020, and the Chinese NMPA granted Breakthrough Therapy designation for MASH in December 2023.

  • Design: NATiV3 (NCT04849728) is a randomised, double-blind, placebo-controlled, multicentre phase 3 trial in adults with biopsy-proven noncirrhotic MASH and F2 or F3 fibrosis. Participants were randomized 1:1:1 to lanifibranor 800 mg or 1200 mg once daily or placebo for 72 weeks, stratified by fibrosis stage (F2, F3) and by presence or absence of type 2 diabetes. The registry record lists 459 locations.
  • Enrollment: the company reports 1,009 participants in the main cohort and 410 in an exploratory cohort of participants with F1 through F4 fibrosis who were histologically not eligible for the main cohort. The registry gives an estimated enrollment of 1000, and the Form 20-F anticipates an NDA for accelerated approval based on liver histological endpoints of approximately 950 patients. In company slides, 67.0% of the main cohort had F3 fibrosis, 55% had type 2 diabetes, 14.0% were taking a GLP-1 receptor agonist, and 10.0% an SGLT2 inhibitor at baseline.
  • Primary endpoint: the registry defines the primary outcome as resolution of NASH and improvement of fibrosis at week 72. Company materials name this composite as the primary endpoint and the two single histologic endpoints as key secondary endpoints, while the Form 20-F financing terms refer to “any key primary endpoint or key secondary endpoint of NATiV3 (resolution of NASH without worsening fibrosis and improvement of liver fibrosis without worsening NASH)”.
  • Extension: the registry describes a 48-week “double-blind active treatment extension”, and the company's last patient visit release describes a “48-week open-label extension period” in which all participants, including those originally randomized to placebo, receive lanifibranor.
  • Status: the company announced that the last participant completed the final 72-week visit and that all participants had completed the 72-week treatment period; the registry lists an actual primary completion date of 2026-09-29. Topline results were expected in the fourth quarter of 2026, and no NATiV3 efficacy results were identified. If results are favorable, the company anticipates a regulatory submission in the first half of 2027 under the FDA accelerated approval pathway and is preparing for a potential U.S. launch in 2028, subject to FDA approval. Accelerated approval and conditional authorization, if granted, require completion of the trial for full approval, and a separate event-driven placebo-controlled phase 3 outcome trial in MASH with compensated cirrhosis, expected to last approximately three years, is planned.
  • Safety reports: the company reported a treatment-related suspected unexpected serious adverse reaction of elevated liver tests, with biopsy results compatible with autoimmune hepatitis; the participant fully recovered. Screening was paused, the protocol was amended to exclude patients diagnosed with or predisposed to autoimmune liver or thyroid disease, and liver monitoring every 6 weeks was added. “Other milder cases of elevation of aminotransferases among trial participants have also been reported.” The Data Monitoring Committee recommended continuing the trial without modification of the protocol.
Summary: NATIVE phase 2b histologic efficacy

NATIVE (NCT03008070) was a phase 2b, double-blind, randomized, placebo-controlled trial in which 247 participants with noncirrhotic, highly active NASH were assigned 1:1:1 to lanifibranor 1200 mg (83), lanifibranor 800 mg (83), or placebo (81) once daily for 24 weeks, with randomization stratified by diabetic status. At baseline, 188 participants (76%) had F2 or F3 fibrosis and 103 (42%) had type 2 diabetes. The primary end point was a decrease of at least 2 points in the SAF-A score without worsening of fibrosis. All biopsy samples were read by one pathologist.

  • Primary end point, full analysis population with multiple imputation (the published primary analysis): 55% with 1200 mg, 48% with 800 mg, and 33% with placebo; risk ratio 1.7 (95% CI, 1.2 to 2.3; P=0.007) for 1200 mg and 1.5 (95% CI, 1.0 to 2.1; P=0.07) for 800 mg.
  • Primary end point, ITT population in the company topline release: 49% (P=0.004) with 1200 mg, 41% (P=0.061) with 800 mg, and 27% with placebo. In the registry results, which count participants with missing data as nonresponders, 41 of 83, 34 of 83, and 22 of 81 participants responded.
  • Secondary histologic end points, multiple imputation: resolution of NASH without worsening of fibrosis in 49%, 39%, and 22% (risk ratios 2.2 and 1.7); improvement in fibrosis of at least 1 stage without worsening of NASH in 48%, 34%, and 29% (risk ratios 1.7, 95% CI 1.2 to 2.5, and 1.2, 95% CI 0.7 to 1.9); and the composite of NASH resolution and fibrosis improvement of at least 1 stage in 35%, 25%, and 9% (risk ratios 4.0 and 2.6), for 1200 mg, 800 mg, and placebo, respectively. No multiplicity adjustments were defined for secondary and exploratory end points.
  • The composite end point is the NATiV3 primary composite endpoint. In the ITT analysis of the topline release, it was met by 31% (1200 mg), 21% (800 mg), and 7% (placebo).
  • Among the 188 participants with F2 or F3 fibrosis (ITT, topline release), resolution of NASH without worsening of fibrosis occurred in 44% (1200 mg), 34% (800 mg), and 9% (placebo). In the company's investor presentation, effect sizes with lanifibranor for resolution of MASH and improvement of fibrosis were 21% (800 mg) and 26% (1200 mg) in participants with type 2 diabetes and 7% and 22%, respectively, in participants without type 2 diabetes.
Summary: NATIVE liver enzyme, metabolic, and patient-reported results

Among the 228 participants who completed week 24 (77, 77, and 74 for 1200 mg, 800 mg, and placebo), adjusted mean changes from baseline were: alanine aminotransferase −24.54, −26.08, and −1.40 U/liter; glycated hemoglobin −0.41, −0.38, and 0.07 percentage points; fasting triglycerides −0.44, −0.49, and 0.06 mmol/liter; fasting HDL cholesterol 0.11, 0.16, and 0.01 mmol/liter; and adiponectin 17.12, 11.95, and −0.35 μg/ml. LDL cholesterol did not change significantly with either dose versus placebo. Scores on the Enhanced Liver Fibrosis test and the Fibrosis-4 index did not improve. No substantial changes from baseline were observed on the SF-36 or the Flinders Fatigue Scale at week 24. Participants with diabetes had histologic improvements similar to those of the full analysis population and greater reductions in fasting glucose, insulin, and glycated hemoglobin.

Summary: NATIVE safety, including weight gain, edema, anemia, and discontinuations

In the full analysis population (83 participants receiving 1200 mg, 83 receiving 800 mg, and 81 receiving placebo), with the treatment period extending to 28 days after the last dose:

  • Adverse events: at least one adverse event in 62 (75%), 59 (71%), and 50 (62%); severe adverse events in 3 (4%) in each group; serious adverse events in 7 (8%), 3 (4%), and 3 (4%); no deaths. The two serious adverse events assessed as related to study treatment (mild heart failure and urticaria) both occurred with placebo. Diarrhea occurred in 10 (12%), 8 (10%), and 1 (1%), and nausea in 7 (8%), 8 (10%), and 3 (4%).
  • Discontinuations: the published report gives discontinuation of the assigned regimen because of adverse events in 3 (4%), 4 (5%), and 3 (4%). The registry participant flow lists adverse events as the reason for not completing in 3, 3, and 3 participants, with one further participant in the 800 mg group listed under withdrawal by patient and adverse event non fatal.
  • Weight: weight gain was reported as an adverse event in 7 (8%), 8 (10%), and 0. Mean body weight increased by 2.7 kg (3.1%) with 1200 mg and by 2.4 kg (2.6%) with 800 mg. Cooreman et al. report for the pooled lanifibranor arms an average weight gain of 2.5 kg; at end of treatment, 51% had stable weight (increase of 2.5% or less), 16% an increase of 2.5% to 5%, and 33% an increase of 5% or more, while 84% of placebo participants had stable weight.
  • Edema: peripheral edema occurred in 7 (8%), 5 (6%), and 2 (2%). Peripheral edema assessed as related to study drug occurred in four participants receiving lanifibranor (two in each group) and in none receiving placebo; one severe case resolved after the 1200 mg regimen was stopped for 12 days and did not recur when treatment resumed. NT-proBNP increased with both doses (adjusted mean difference versus placebo 8.4 pmol/L with 1200 mg and 4.0 pmol/L with 800 mg), and the authors report no clinical evidence of congestion. The investigator reported nontreatment-related mild heart failure in one participant receiving 1200 mg.
  • Anemia: anemia occurred in 6 (7%), 1 (1%), and 0. In the six participants with anemia in the 1200 mg group, hemoglobin returned to pretreatment values after investigator-initiated iron supplementation or discontinuation of lanifibranor. The relative reduction in hemoglobin from baseline was 5 to 6% with lanifibranor and 1% with placebo.
  • Kidney function and bone turnover markers were not impaired.
Summary: LEGEND and NCT03459079 results

LEGEND (NCT05232071) was a phase 2, three-arm, randomized trial in adults with noncirrhotic MASH and type 2 diabetes (screening HbA1c 7.0% to 10.0%), double-blind for lanifibranor 800 mg and placebo and open-label for lanifibranor 800 mg plus empagliflozin 10 mg, with 24 weeks of treatment. Of 63 planned participants, 39 were treated (12 lanifibranor, 13 combination, 14 placebo); recruitment was stopped after the interim analysis because the primary endpoint was met. The registry lists 12, 12, and 9 completers, and the poster lists 11 completers in the combination arm.

  • Primary endpoint, final registry analysis (mixed model for repeated measures): least squares mean change in HbA1c from baseline to week 24 of −1.11 percentage points with lanifibranor (n=11), −1.54 with the combination (n=13), and 0.16 with placebo (n=13); least squares mean differences versus placebo of −1.27 and −1.7 (both p < 0.001).
  • Primary endpoint, interim analysis (March 2024, full analysis set of 11, 10, and 9 participants): −1.14, −1.59, and +0.26.
  • In the poster, 50% of participants in both active arms reached HbA1c below 6.5% at week 24, and 58% (lanifibranor) and 80% (combination) had an HbA1c decrease of at least 1%, versus 0% with placebo. MRI-PDFF relative changes were −49% and −41%.
  • Safety: relative body weight change was 3.6% with lanifibranor, 0.25% with the combination, and −1.16% with placebo. Anemia occurred in 2 of 12, 0 of 13, and 1 of 14 participants, and peripheral edema in 0 of 12, 1 of 13, and 0 of 14. There were no deaths; one serious adverse event (haematuria) occurred in the combination arm. Inventiva does not expect to study the combination further and expects to include the LEGEND safety data in a potential submission for marketing approval.

NCT03459079 was a single-center, double-blind, placebo-controlled, 24-week trial at the University of Florida, financially supported by Inventiva, in which 38 adults with type 2 diabetes and MASLD (intrahepatic triglyceride content of at least 10% by proton magnetic resonance spectroscopy) were randomized to lanifibranor 800 mg (20) or placebo (18). The registry lists an actual enrollment of 128, of whom 38 were randomized. The study did not seek to recruit patients with fibrosis stage F2 or higher, and 28 participants completed it.

  • Primary endpoint, absolute change in intrahepatic triglyceride content, full analysis set: −8.7% with lanifibranor and −3.0% with placebo in the published report, and −10.1% and −1.4% in the 2023 congress poster; both report a least squares mean difference of −5.6% (95% CI −9.6 to −1.7%; p = 0.007). The relative change was −44% versus −12%. A reduction of at least 30% occurred in 65% versus 22%, and steatosis resolution (intrahepatic triglyceride content of 5.5% or less) in 25% versus 0%.
  • HbA1c changed by −0.7 versus −0.1 percentage points (adjusted least squares mean difference −0.6; p <0.001), and adiponectin increased 2.4-fold with lanifibranor.
  • Safety: mean weight change was +2.7% with lanifibranor and −1.0% with placebo. Adverse events led to discontinuation in 4 of 20 (20%) and 2 of 18 (11%), anemia occurred in 4 (20%) and 2 (11%), and edema in 1 (5%) and 0. One serious adverse event under lanifibranor was assessed as unrelated to study drug.
Summary: pharmacology, dosing studied, and interaction exclusions
  • Mechanism: lanifibranor is designed to activate all three PPAR isoforms, with balanced activation of PPARα and PPARδ and partial activation of PPARγ. Reported EC50 values at human PPARs were 1.63E‐06 M (α), 8.49E‐07 M (δ), and 2.28E‐07 M (γ), with maximal effects of 100% at PPARα and PPARδ and 80% at PPARγ relative to fenofibrate, GW501516, and rosiglitazone, respectively. Kamata et al. state that PPARγ-related effects (weight gain, edema, bone loss, and congestive heart failure) should be closely monitored.
  • Dosing studied: 800 mg or 1200 mg once daily as 400 mg film-coated immediate-release tablets taken with food (three tablets daily in NATIVE and NATiV3, with one placebo tablet in the 800 mg arm); doses were selected from adiponectin, HDL cholesterol, and triglyceride results in a phase 2a study in type 2 diabetes. Dose modification was not permitted in NATIVE; LEGEND allowed one interruption of up to 15 days for adverse events. In a QT/QTc study in 217 healthy participants, 1200 and 2400 mg/day did not prolong the QT interval.
  • Pharmacokinetics: maximum concentrations at about 1.0 to 3.5 h, terminal half-life of around 10 to 15 h, steady state by day 3 without significant accumulation, and exposure increasing slightly less than dose-proportionally. Plasma protein binding was about 99.9% in all tested species, elimination is mainly faecal (more than 85%) with urinary excretion below 7%, and a food effect was observed with a high-fat breakfast. Cmax was 22% and AUC 39% higher in elderly than in young participants.
  • Interactions: in vitro, lanifibranor is metabolized mainly by CYP2C8, CYP2C19, and CYP3A4 and by UGT 2B7, 1A1, and 1A3, and inhibits CYP2C8 (IC50 4 µM), CYP2C9 (8 µM), CYP2C19 (25 µM), and CYP2B6 (8 µM). No significant interaction with simvastatin was observed (less than 2-fold). The LEGEND protocol prohibits strong CYP2C8 inducers (for example, rifampin) and strong CYP2C8 inhibitors (for example, gemfibrozil and clopidogrel), and an amendment driven by preliminary results of drug-drug interaction study 337HVPK21014 also excludes substrates of CYP2B6 and CYP2C8; no published results of that study were identified. NATiV3 excludes concomitant fibrates, thiazolidinediones within 12 months, insulin, and any approved treatment for NASH or obesity, and permits GLP-1 receptor agonists, SGLT2 inhibitors, and statins taken for at least 3 months.
  • Trial exclusions relevant to use include hemoglobin below 110 g/L in women or 120 g/L in men, a history of heart failure with reduced ejection fraction, and a diagnosis of or predisposition to autoimmune liver or thyroid disease. The tablets contain lactose monohydrate.